Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.

Mazarei G, Leavitt BR.

J Huntingtons Dis. 2015;4(2):109-18. doi: 10.3233/JHD-159003. Review.

2.

The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.

Mazarei G, Budac DP, Lu G, Lee H, Möller T, Leavitt BR.

Exp Neurol. 2013 Nov;249:144-8. doi: 10.1016/j.expneurol.2013.08.007. Epub 2013 Aug 30.

PMID:
23994717
3.

Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.

Mazarei G, Budac DP, Lu G, Adomat H, Tomlinson Guns ES, Möller T, Leavitt BR.

J Neurochem. 2013 Dec;127(6):852-67. doi: 10.1111/jnc.12350. Epub 2013 Jul 15.

4.

Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.

Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, Lu G, Leavitt BR, Hayden MR.

J Neurosci. 2010 Oct 27;30(43):14318-29. doi: 10.1523/JNEUROSCI.1589-10.2010.

5.

Expression analysis of novel striatal-enriched genes in Huntington disease.

Mazarei G, Neal SJ, Becanovic K, Luthi-Carter R, Simpson EM, Leavitt BR.

Hum Mol Genet. 2010 Feb 15;19(4):609-22. doi: 10.1093/hmg/ddp527. Epub 2009 Nov 23.

6.

X-linked myopathy: when autophagy goes wrong.

Mazarei G.

Clin Genet. 2010 Feb;77(2):114-5. doi: 10.1111/j.1399-0004.2009.01303.x. Epub 2009 Nov 11. No abstract available.

PMID:
19912261

Supplemental Content

Loading ...
Support Center